P-374 Impact of different luteal phase support protocols in fresh embryo transfers on perinatal outcomes of singleton in vitro fertilization pregnancies: a three-decade experience.

Abstract Study question How can stimulation of corpus luteum in the luteal phase with human chorionic gonadotropin (hCG) improve obstetric and perinatal outcomes? Summary answer There is currently no evidence that use hCG as an alternative treatment for luteal-phase support (LPS) improves outcomes. What known already are different approaches providing LPS, although none have shown differences pregnancy rates. However, emerging has also revealed important role outcomes after vitro fertilization (IVF) (preeclampsia or intrauterine growth restriction, among others) production progesterone (can be administered exogenously) well secretion multiple vasoactive active substances. design, size, duration We performed a retrospective, single centre study between 1991-2021. A total 2592 singleton pregnancies were analysed fresh embryo-transfer according to LPS. Participants/materials, setting, methods IVF stratified into two cohorts LPS protocol: 1) trigger 5000 IU urinary (U-hCG) protocol 200 mg x3/day/vaginally beginning day oocyte retrieval one u-hCG bolus 2500 IU, 3 days retrieval; 2) 250 µgr recombinant only (200 x3/day/ vaginally). Main results chance compared reproductive cycles cohort n = 527 2065. The three groups maternal age reduce possible bias: 35 years old less, 36 39 old, 40 more old. In 1, all followed long agonist GnRH protocol, while 2, 78.11% received 21.89 % antagonist protocol. Recombinant gonadotropins ovarian was cycles. observed greater number eutocic deliveries, lower instrumentalized births stable caesarean rate along period. statistical regarding hypertensive disorders, small gestational large age. Group 2 showed apparent tendency, albeit not significant, preeclampsia significant increase very preterm birth. Emerging following IVF. Limitations, reasons caution evaluated clear strength this study. This first series comparing contrast, retrospective design time period involving changes laboratory patient profiles limitation. Wider implications findings optimization treatments especially related factors, including individualization ensure safety derived thereof. More studies on protocols available needed. Trial registration applicable